Literature DB >> 10798670

Squalamine improves retinal neovascularization.

R D Higgins1, R J Sanders, Y Yan, M Zasloff, J I Williams.   

Abstract

PURPOSE: Modalities for inhibiting neovascularization may be one avenue to the development of effective therapies for retinopathy. The effect of squalamine, an antiangiogenic amino sterol, on oxygen-induced retinopathy (OIR) was assessed in a mouse model.
METHODS: OIR was induced in C57BL6 mice by a 5-day exposure to 75% oxygen from postnatal day (P)7 through P12. Squalamine (25 mg/kg, subcutaneous)treated animals received either daily doses for five days from P12 to P16 or one dose just after removal from oxygen on P12. Each set of animals was killed at P17 to P21. Retinopathy was assessed with a retinopathy scoring system evaluation of retinal wholemounts and by quantification of neovascular nuclei on retinal sections.
RESULTS: Animals receiving 5 days of squalamine after a 5-day exposure to oxygen had total retinopathy scores (expressed as median score with 25th and 75th quartiles in parentheses) of 4(3, 5) versus oxygen-only-reared animals with scores of 8(7, 9; P < 0.001). Animals reared in room air and animals exposed to squalamine only had similar retinopathy scores: 1(1, 2) and 1(0, 2). Oxygen-reared animals receiving single-dose squalamine also showed improvement, with a median retinopathy score of 4(4, 6.75) versus oxygen-only-reared animals with median retinopathy score of 9(7, 10; P < 0.001). There was a decreased number of neovascular nuclei extending beyond the inner limiting membrane on retinal sections in animals treated with 5 days (P < 0.01) and 1 day (P < 0.001) of squalamine.
CONCLUSIONS: Squalamine significantly improved retinopathy and may be a novel agent for effective treatment of ocular neovascularization.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10798670

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  5 in total

1.  Squalamine as a broad-spectrum systemic antiviral agent with therapeutic potential.

Authors:  Michael Zasloff; A Paige Adams; Bernard Beckerman; Ann Campbell; Ziying Han; Erik Luijten; Isaura Meza; Justin Julander; Abhijit Mishra; Wei Qu; John M Taylor; Scott C Weaver; Gerard C L Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

Review 2.  Current and future treatment options for nonexudative and exudative age-related macular degeneration.

Authors:  Grant M Comer; Thomas A Ciulla; Mark H Criswell; Michael Tolentino
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 3.  Squalamine and Its Aminosterol Derivatives: Overview of Biological Effects and Mechanisms of Action of Compounds with Multiple Therapeutic Applications.

Authors:  Nour Mammari; Elsa Salles; Audrey Beaussart; Sofiane El-Kirat-Chatel; Mihayl Varbanov
Journal:  Microorganisms       Date:  2022-06-13

4.  Age-related macular degeneration: experimental and emerging treatments.

Authors:  Jean Pierre Hubschman; Shantan Reddy; Steven D Schwartz
Journal:  Clin Ophthalmol       Date:  2009-06-02

5.  A novel small molecule ameliorates ocular neovascularisation and synergises with anti-VEGF therapy.

Authors:  Rania S Sulaiman; Stephanie Merrigan; Judith Quigley; Xiaoping Qi; Bit Lee; Michael E Boulton; Breandán Kennedy; Seung-Yong Seo; Timothy W Corson
Journal:  Sci Rep       Date:  2016-05-05       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.